Page 22 - Read Online

Page 12 of 12 Yu et al. Hepatoma Res. 2025;11:29 | https://dx.doi.org/10.20517/2394-5079.2025.47

14. Diehl A, Yarchoan M, Hopkins A, Jaffee E, Grossman SA. Relationships between lymphocyte counts and treatment-related toxicities
and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. Oncotarget. 2017;8:114268-80. DOI
PubMed PMC
15. Egami S, Kawazoe H, Hashimoto H, et al. Absolute lymphocyte count predicts immune-related adverse events in patients with non-
small-cell lung cancer treated with nivolumab monotherapy: a multicenter retrospective study. Front Oncol. 2021;11:618570. DOI
PubMed PMC
16. Aso K, Kono M, Kanda M, et al. Itaconate ameliorates autoimmunity by modulating T cell imbalance via metabolic and epigenetic
reprogramming. Nat Commun. 2023;14:984. DOI PubMed PMC
17. Eschweiler S, Ramírez-Suástegui C, Li Y, et al. Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs. Nature.
2022;605:741-6. DOI PubMed PMC
18. Lepper A, Bitsch R, Özbay Kurt FG, et al. Melanoma patients with immune-related adverse events after immune checkpoint inhibitors
are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs. Oncoimmunology. 2023;12:2247303.
DOI PubMed PMC
19. Liu J, Blake SJ, Harjunpää H, et al. Assessing immune-related adverse events of efficacious combination immunotherapies in
preclinical models of cancer. Cancer Res. 2016;76:5288-301. DOI PubMed
20. Isik B, Alexander MP, Manohar S, et al. Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-
related adverse events. Kidney Int Rep. 2021;6:1022-31. DOI PubMed PMC
21. Dharmapuri S, Özbek U, Jethra H, et al. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of
immune treatment related toxicity in hepatocellular carcinoma. World J Gastrointest Oncol. 2023;15:1900-12. DOI PubMed PMC
22. Pavan A, Calvetti L, Dal Maso A, et al. Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell
lung cancer treated with immune-checkpoint inhibitors. Oncologist. 2019;24:1128-36. DOI PubMed PMC
23. Lee PY, Oen KQX, Lim GRS, et al. Neutrophil-to-lymphocyte ratio predicts development of immune-related adverse events and
outcomes from immune checkpoint blockade: a case-control study. Cancers. 2021;13:1308. DOI PubMed PMC
24. Fujimoto A, Toyokawa G, Koutake Y, et al. Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related
adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer. Thorac Cancer. 2021;12:2198-204.
DOI PubMed PMC
25. Sue M, Takeuchi Y, Hirata S, Takaki A, Otsuka M. Impact of nutritional status on neutrophil-to-lymphocyte ratio as a predictor of
efficacy and adverse events of immune check-point inhibitors. Cancers. 2024;16:1811. DOI PubMed PMC
26. Takada S, Murooka H, Tahatsu K, et al. Identifying early predictive markers for immune-related adverse events in nivolumab-treated
patients with renal cell carcinoma and gastric cancer. Asian Pac J Cancer Prev. 2022;23:695-701. DOI PubMed PMC